CytoSig: Novel Software Platform Predictor of Cytokine Signaling Activity and Target Discovery

Presentation/Conference

May 25, 2022 11:00 a.m. - 12:00 p.m. ET

Dr. Peng Jiang of NCI’s Center for Cancer Research will discuss CytoSig, a software-based platform that is designed to provide both a database of target genes modulated by cytokines (i.e., proteins secreted by certain cells of the immune system and have an effect on other cells) and a predictive model of cytokine signaling cascades from transcriptomic profiles. Business and drug development professionals, researchers, and investors are encouraged to attend this event.

CytoSig covers over 20,000 curated human cytokine, chemokine, and growth factor response experiments, and can solve challenges by reliably predicting the activity of 43 cytokines in both tissues and single cells based on the transcriptional effect of target genes.

NCI is seeking parties interested in licensing and/or co-development of CytoSig, which solves challenges by:

offering significantly larger database content coverage and use of transcriptome data to model cytokine signaling activity and regulatory cascades in human inflammatory processes.
coupling large-scale automatic data processing with natural language processing functions to assist expert metadata annotations with RNA-sequencing and MicroArray big-data analysis.

Peng Jiang, Ph.D.

Dr. Jiang is a Stadtman investigator for NCI’s Center for Cancer Research, Cancer Data Science Laboratory. In his research, he focuses on developing integrative frameworks that leverage the big-data resource in public domains to identify regulators of cancer therapy resistance. His team is developing statistical and machine learning infrastructures that transfer knowledge from a vast amount of previous data cohorts to the study of new cancer biology problems.